Skip to main content

Table 1 Baseline characteristics of the eligible patients (n = 142)

From: Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective study

Clinicopathological characteristics

Total (n=142)

SLNB alone (n=115)

ALND (n=27)

Age (median, range)

52 years (26–82)

52 years (29–82)

44 years (26–69)

Age group, no. (%)

 ≤ 50

68 (47.89)

51 (44.35)

17 (62.96)

 > 50

74 (52.11)

64 (55.65)

10 (37.04)

Clinical T stage, no. (%)

 cT1

112 (78.87)

90 (78.26)

22 (81.48)

 cT2

30 (21.13)

25 (21.74)

5 (18.52)

Pathological T stage, no. (%)

 pT1

103 (72.54)

81 (70.43)

22 (81.48)

 pT2

39 (33.91)

34 (29.57)

5 (18.52)

Tumor histology, no. (%)

 Ductal

119 (83.80)

95 (82.61)

24 (88.89)

 Lobular

15 (10.56)

13 (11.30)

2 (7.41)

 Other

8 (5.63)

7 (6.09)

1 (3.7)

Lymphovascular invasion, no. (%)

 Present

33 (23.24)

26 (22.61)

7 (25.93)

 Absent

68 (47.89)

60 (52.17)

8 (29.63)

 Missing

41 (28.87)

29 (25.22)

12 (44.44)

Hormone status, no. (%)

 Positive

117 (82.39)

92 (80.0)

25 (92.59)

 Negative

25 (17.61)

23 (20.0)

2 (7.41)

HER2 status, no. (%)

 Negative

118 (83.10)

96 (83.48)

22 (81.48)

 Positive

21 (14.79)

17 (14.78)

4 (14.81)

 Unknown

3 (2.11)

2 (1.74)

1 (3.70)

Number of positive SLN, no. (%)

 1

109 (76.76)

94 (81.74)

15 (55.56)

 2

33 (23.24)

21 (18.26)

12 (44.44)

Adjuvant chemotherapy, no. (%)

 Yes

129 (90.45)

102 (88.70)

27 (100.00)

 No

13 (9.15)

13 (11.30)

0 (0.00)

Adjuvant endocrine therapy, no. (%)

 Yes

115 (80.99)

92 (80.00)

23 (85.19)

 No

27 (19.01)

23 (20.00)

4 (14.81)

Radiotherapy, no. (%)

 Yes

127 (89.44)

101 (87.83)

26 (96.30)

 No

15 (10.56)

14 (12.17)

1 (3.70)